Your browser doesn't support javascript.
loading
Docetaxel for Nonmetastatic Prostate Cancer: Long-Term Survival Outcomes in the STAMPEDE Randomized Controlled Trial.
James, Nicholas D; Ingleby, Fiona C; Clarke, Noel W; Amos, Claire L; Attard, Gerhardt; Brawley, Christopher D; Chowdhury, Simon; Cross, William; Dearnaley, David P; Gilbert, Duncan C; Gillessen, Silke; Jones, Robert J; Langley, Ruth E; Macnair, Archie; Malik, Zafar I; Mason, Malcolm D; Matheson, David J; Millman, Robin; Parker, Chris C; Rush, Hannah L; Russell, J Martin; Au, Carly; Ritchie, Alastair W S; Mestre, Ricardo Pereira; Ahmed, Imtiaz; Birtle, Alison J; Brock, Susannah J; Das, Prantik; Ford, Victoria A; Gray, Emma K; Hughes, Robert J; Manetta, Caroline B; McLaren, Duncan B; Nikapota, Ashok D; O'Sullivan, Joe M; Perna, Carla; Peedell, Clive; Protheroe, Andrew S; Sundar, Santhanam; Tanguay, Jacob S; Tolan, Shaun P; Wagstaff, John; Wallace, Jan B; Wylie, James P; Zarkar, Anjali; Parmar, Mahesh K B; Sydes, Matthew R.
Afiliación
  • James ND; Division of Radiotherapy and Imaging, The Institute of Cancer Research and Royal Marsden NHS Foundation Trust, London, UK.
  • Ingleby FC; MRC Clinical Trials Unit at University College London (UCL), Institute of Clinical Trials and Methodology, UCL, London, UK.
  • Clarke NW; The Christie and Salford Royal Hospitals, Manchester, UK.
  • Amos CL; MRC Clinical Trials Unit at University College London (UCL), Institute of Clinical Trials and Methodology, UCL, London, UK.
  • Attard G; UCL Cancer Institute, London, UK.
  • Brawley CD; MRC Clinical Trials Unit at University College London (UCL), Institute of Clinical Trials and Methodology, UCL, London, UK.
  • Chowdhury S; Guy's and St. Thomas' NHS Foundation Trust, London, UK.
  • Cross W; Sarah Cannon Research Institute, London, UK.
  • Dearnaley DP; St James's University Hospital, Leeds, UK.
  • Gilbert DC; Division of Radiotherapy and Imaging, The Institute of Cancer Research and Royal Marsden NHS Foundation Trust, London, UK.
  • Gillessen S; MRC Clinical Trials Unit at University College London (UCL), Institute of Clinical Trials and Methodology, UCL, London, UK.
  • Jones RJ; Istituto Oncologico della Svizzera Italiana, Bellinzona, Switzerland.
  • Langley RE; Institute of Cancer Sciences, University of Glasgow, Beatson West of Scotland Cancer Centre, Glasgow, UK.
  • Macnair A; MRC Clinical Trials Unit at University College London (UCL), Institute of Clinical Trials and Methodology, UCL, London, UK.
  • Malik ZI; MRC Clinical Trials Unit at University College London (UCL), Institute of Clinical Trials and Methodology, UCL, London, UK.
  • Mason MD; Guy's and St. Thomas' NHS Foundation Trust, London, UK.
  • Matheson DJ; The Clatterbridge Cancer Centre NHS Foundation Trust, Bebington, UK.
  • Millman R; School of Medicine, Cardiff University, Cardiff, UK.
  • Parker CC; Faculty of Education, Health and Wellbeing, University of Wolverhampton, Wolverhampton, UK.
  • Rush HL; MRC Clinical Trials Unit at University College London (UCL), Institute of Clinical Trials and Methodology, UCL, London, UK.
  • Russell JM; Division of Radiotherapy and Imaging, The Institute of Cancer Research and Royal Marsden NHS Foundation Trust, London, UK.
  • Au C; MRC Clinical Trials Unit at University College London (UCL), Institute of Clinical Trials and Methodology, UCL, London, UK.
  • Ritchie AWS; Guy's and St. Thomas' NHS Foundation Trust, London, UK.
  • Mestre RP; Institute of Cancer Sciences, University of Glasgow, Beatson West of Scotland Cancer Centre, Glasgow, UK.
  • Ahmed I; MRC Clinical Trials Unit at University College London (UCL), Institute of Clinical Trials and Methodology, UCL, London, UK.
  • Birtle AJ; Urology Department, Gloucestershire Royal NHS Foundation Trust, Gloucester, UK (retired).
  • Brock SJ; Oncology Institute of Southern Switzerland, Bellinzona, Switzerland.
  • Das P; Institute of Oncology Research (IOR), Bellinzona, Switzerland.
  • Ford VA; Southend University NHS Trust, Southend, UK.
  • Gray EK; Rosemere Cancer Centre Lancs Teaching Hospitals, Preston, UK.
  • Hughes RJ; University of Manchester, Manchester, UK.
  • Manetta CB; University of Central Lancashire (UCLan), Lancaster, UK.
  • McLaren DB; University Hospital Dorset, Cardiff, UK.
  • Nikapota AD; University Hospitals of Derby NHS Foundation Trust, Derby, UK.
  • O'Sullivan JM; Royal Devon and Exeter NHS Foundation Trust, Exeter, UK.
  • Perna C; Musgrove Park Hospital, Taunton, UK.
  • Peedell C; Mount Vernon Cancer Centre, Cardiff, UK.
  • Protheroe AS; Sussex Cancer Centre, University Hospitals Sussex, Brighton, UK.
  • Sundar S; Edinburgh Cancer Centre, Western General Hospital, Edinburgh, UK.
  • Tanguay JS; Sussex Cancer Centre, University Hospitals Sussex, Brighton, UK.
  • Tolan SP; Worthing and Southlands Hospital, Worthing, UK.
  • Wagstaff J; Patrick G. Johnston Centre for Cancer Research, Queen's University Belfast, Belfast, UK.
  • Wallace JB; Royal Surrey NHS Foundation Trust, Guildford, UK.
  • Wylie JP; James Cook University Hospital, Middlesbrough, UK.
  • Zarkar A; Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
  • Parmar MKB; Nottingham University Hospitals NHS Trust, Nottingham, UK.
  • Sydes MR; Velindre Cancer Centre, Cardiff, UK.
JNCI Cancer Spectr ; 6(4)2022 07 01.
Article en En | MEDLINE | ID: mdl-35877084
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Neoplasias de la Próstata Tipo de estudio: Clinical_trials Límite: Humans / Male Idioma: En Revista: JNCI Cancer Spectr Año: 2022 Tipo del documento: Article País de afiliación: Reino Unido
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Neoplasias de la Próstata Tipo de estudio: Clinical_trials Límite: Humans / Male Idioma: En Revista: JNCI Cancer Spectr Año: 2022 Tipo del documento: Article País de afiliación: Reino Unido